MyMyelomaTeam

Several breakthrough treatments have recently emerged for multiple myeloma. CAR T-cell therapy has shown impressive results, with ide-cel helping 73% of patients and ciltacabtagene autoleucel showing improvements in nearly 98% of study participants. These therapies work by modifying a person's own T cells to better target Show Full Answer

Several breakthrough treatments have recently emerged for multiple myeloma. CAR T-cell therapy has shown impressive results, with ide-cel helping 73% of patients and ciltacabtagene autoleucel showing improvements in nearly 98% of study participants. These therapies work by modifying a person's own T cells to better target myeloma cells. Three new bispecific antibodies have been FDA-approved as of February 2025: elranatamab-bcmm (Elrexfio), talquetamab (Talvey), and teclistamab-cqyv (Tecvayli). These innovative treatments help the immune system more effectively attack cancer cells by targeting two different proteins simultaneously - one on myeloma cells and one on T cells. Additional targeted therapies include monoclonal antibodies like daratumumab, elotuzumab, and isatuximab, as well as proteasome inhibitors. These treatments specifically target cancerous plasma cells while sparing healthy ones, representing a significant advancement in myeloma treatment.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

New Treatment Options for Relapsed or Refractory Myeloma

Relapsed vs. Refractory Myeloma: 5 Facts To Know